On Demand Webinar

Acute myeloid leukemia (AML) poses a significant therapeutic challenge, with a rising incidence in recent times. This clonal hematopoietic disorder of progenitor and stem cells exhibits aggressive behavior, and despite initial remission, recurrence is common. The conventional shift from chemotherapy to monoclonal antibodies and antibody-drug conjugates (ADCs) has been hindered by the absence of AML-specific antigens. Notably, CD33, expressed strongly in 80–90% of AML cells, has become a target for gemtuzumab-ozogamicin (Mylotarg), the sole FDA-approved ADC for AML treatment.

While advancements in understanding AML molecular mechanisms have influenced clinical approaches, the lack of clinically representative models hinders therapeutic progress. Existing models, both in vivo and ex vivo, struggle to capture the heterogeneity and complexity of AML. Addressing this, we present our proprietary assay, Champions’ AML VitroScreen, designed for testing therapeutic candidates in primary AML samples. Our diverse bank of deeply characterized AML samples encompasses multiple subtypes, allowing the evaluation of therapeutic responses through cell viability, proliferation, and clonal composition analyses.

In this Poster QuickTake, we take a deep dive into the correlation between gemtuzumab-ozogamicin efficacy and CD33+ expression in AML primary samples using Champions' novel AML VitroScreen.

Meet Our Presenter:

Mara Gilardi, PhD, Immuno-oncology Subject Matter Expert, Champions Oncology

At the helm of Champions Oncology's immunology division, Mara synthesizes over 3 years of dedicated effort in translating cutting-edge research into clinical applications. Her core competencies include in-depth tumor microenvironment profiling with multiomics data, the development of ex vivo 2D-3D models and in vivo orthotopic models in immunodeficient and humanized animals, IHC and multiplex analysis and biomarker identification, which are instrumental in advancing our understanding and treatment of cancer.

Her mission is to bridge the gap between laboratory discoveries and patient care, driven by the ethical application of science and a commitment to improving clinical outcomes. Collaborating with industry leaders and our commercial and scientific teams, I am focused on fostering innovative R&D and marketing strategies while contributing to developing next-generation therapies.